Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.45 |
| ▸ | STS | P08842 | 5/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4551423 | 0.90 | HPGD (0.45) | HPGDRECQLEPHX1GPR119STS | |
| SCHEMBL1514778 | 0.89 | EPHX1 (0.52) | HPGDRECQLEPHX1GPR119STS | |
| SCHEMBL1088787 | 0.83 | GPR119 (0.46) | HPGDRECQLEPHX1GPR119STS | |
| SCHEMBL16497005 | 0.82 | HPGD (0.48) | HPGDRECQLEPHX1GPR119STS | |
| SCHEMBL25176980 | 0.80 | NR1H2 (0.43) | HPGDRECQLEPHX1GPR119STS | |
| SCHEMBL8624108 | 0.80 | HPGD (0.46) | HPGDRECQLEPHX1GPR119STS | |
| SCHEMBL1180780 | 0.80 | EPHX1 (0.47) | HPGDRECQLEPHX1GPR119STS | |
| SCHEMBL15477857 | 0.80 | HPGD (0.46) | HPGDRECQLEPHX1GPR119STS | |
| SCHEMBL189924 | 0.80 | RECQL (0.55) | HPGDRECQLEPHX1GPR119STS | |
| Methane SCHEMBL28121361 | 0.80 | HPGD (0.54) | HPGDRECQLEPHX1GPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | HPGD 1034/4885RECQL 3885/4885EPHX1 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.